This webinar takes place on Thursday March 12 between 16.00 and 16.30 CET / 15.00-15.30 GMT / 11.00-11.30 AM EDT / 8.00-8.30 AM PDT.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Antisense oligonucleotides (ASOs) have emerged as promising therapeutic solutions for genetically well-defined central nervous system (CNS) diseases, as exemplified by Nusinersen, a life altering therapeutic for people living with Spinal Muscular Atrophy. However, ASO administration into the CNS can result in delayed onset toxicity, driven by either direct neuronal toxicity or by neuroinflammatory processes that can appear months after the initial administration. There are examples of severe adverse events like these from both clinically failed molecules and approved ASO therapies. This points to the need for more predictive in vitro assays that can be used at an early stage in drug discovery.

Cellectricon has developed a broad range of assays for assessing effects of numerous modalities such as neuronal function, cellular phenotype, and the immune response. In this webinar, we will present how our neuroinflammation platform has the potential to be utilized to identify ASOs with delayed onset adverse effects, as well as how the phenotypic readouts can be utilized to increase the understanding with regards to the cellular origin of the toxicity.

Presented by:

Johan Pihl, CSO

Johan joined Cellectricon in 2005 and has been in R&D as well as commercial positions at the company. He has been involved in the development of Cellectricon’s proprietary technology platforms and intellectual property. Prior to his role as Chief Scientific Officer at Cellectricon, he was developing and overseeing the discovery services as Chief Operating Officer. Johan has a PhD in Chemistry from Chalmers University of Technology, Gothenburg, Sweden, and is the author and co-author of numerous scientific publications and patents.